The thromboxane receptor antagonist S18886 attenuates renal oxidant stress and proteinuria in diabetic apolipoprotein E-deficient mice

Diabetes

Volumn 55, Issue 1, 2006, Pages 110-119

  Xu, Shanqin ^a   Jiang, Bingbing ^a   Maitland, Karlene A ^a   Bayat, Hossein ^a   Gu, Jiali ^b   Nadler, Jerry L ^b   Corda, Stefano ^c   Lavielle, Gilbert ^c   Verbeuren, Tony J ^d   Zuccollo, Adriana ^a   Cohen, Richard A ^a,e  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

^c INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

^d INSTITUT DE RECHERCHES SERVIER   (France)

^e BOSTON UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

12 HYDROXYICOSATETRAENOIC ACID; 3 NITROTYROSINE; 8 ISOPROSTAGLANDIN F2 ALPHA; ACETYLSALICYLIC ACID; APOLIPOPROTEIN E; ARACHIDONATE 12 LIPOXYGENASE; INDUCIBLE NITRIC OXIDE SYNTHASE; LYSINE ACETYLSALICYLATE; MANGANESE SUPEROXIDE DISMUTASE; PROSTAGLANDIN SYNTHASE; PROTEIN P47; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; S 18886; THROMBOXANE RECEPTOR BLOCKING AGENT; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DRUG EFFECT; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME SUBUNIT; EXTRACELLULAR MATRIX; FEMALE; HISTOPATHOLOGY; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; IMMUNOHISTOCHEMISTRY; INFLAMMATION; MICROALBUMINURIA; MOUSE; NITRATION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEINURIA; RECEPTOR BLOCKING; URINE LEVEL;

EID: 33644746320     PISSN: 00121797     EISSN: 00121797     Source Type: Journal    
DOI: 10.2337/diabetes.55.01.06.db05-0831     Document Type: Article

References (46)

1. Thuraisingham RC, Nott CA, Dodd SM, Yaqoob MM: Increased nitrotyrosine staining in kidneys from patients with diabetic nephropathy. Kidney Int 57:1968-1972, 2000
2. phox by protein kinase C-β activation is required for oxidative stress in diabetic nephropathy. Diabetes 52:2603-2614, 2003
3. Onozato ML, Tojo A, Goto A, Fujita T, Wilcox CS: Oxidative stress and nitric oxide synthase in rat diabetic nephropathy: effects of ACEI and ARB. Kidney Int 61:186-194, 2002
4. 2+ superoxide dismutase protects against early diabetic glomerular injury in transgenic mice. Diabetes 50:2114-2125, 2001
5. DeRubertis FR, Craven PA, Melhem MF, Salah EM: Attenuation of renal injury in db/db mice overexpressing superoxide dismutase: evidence for reduced superoxide-nitric oxide interaction. Diabetes 53:762-768, 2004
6. Kang SW, Adler SG, Nast CC, LaPage J, Gu JL, Nadler JL, Natarajan R: 12-lipoxygenase is increased in glucose-stimulated mesangial cells and in experimental diabetic nephropathy. Kidney Int 59:1354-1362, 2001
7. Beckman JS, Koppenol WH: Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly. Am J Physiol 271:C1424-C1437, 1996
8. Antonipillai I, Nadler J, Vu EJ, Bughi S, Natarajan R, Horton R: A 12-lipoxygenase product, 12-hydroxyeicosatetraenoic acid, is increased in diabetics with incipient and early renal disease. J Clin Endocrinol Metab 81:1940-1945, 1996
9. Natarajan R, Reddy MA: HETEs/EETs in renal glomerular and epithelial cell functions. Curr Opin Pharmacol 3:198-203, 2003
10. Craven PA, Melhem MF, DeRubertis FR: Thromboxane in the pathogenesis of glomerular injury in diabetes. Kidney Int 42:937-946, 1992
11. Patrono C, FitzGerald GA: Isoprostanes: potential markers of oxidant stress in atherothrombotic disease. Arterioscler Thromb Vasc Biol 17:2309-2315, 1997
12. 2α and platelet activation in diabetes mellitus: effects of improved metabolic control and vitamin E supplementation. Circulation 99:224-229, 1999
13. 2 receptor in vivo. Circulation 101:2833-2840, 2000
14. Matsuo Y, Takagawa I, Koshida H, Kawabata T, Nakamura M, Ida T, Zhou L, Marumo F: Antiproteinuric effect of a thromboxane receptor antagonist, S-1452, on rat diabetic nephropathy and murine lupus nephritis. Pharmacology 50:1-8, 1995
15. Khajehdehi P, Roozbeh J, Mostafavi H: A comparative randomized and placebo-controlled short-term trial of aspirin and dipyridamole for overt type-2 diabetic nephropathy. Scand J Urol Nephrol 36:145-148, 2002
16. Winchester JF: Therapeutic uses of aspirin in renal diseases. Am J Kidney Dis 28:S20-S23, 1996
17. Cayatte AJ, Du Y, Oliver-Krasinski J, Lavielle G, Verbeuren TJ, Cohen RA: The thromboxane receptor antagonist S18886 but not aspirin inhibits atherogenesis in apoE-deficient mice: evidence that eicosanoids other than thromboxane contribute to atherosclerosis. Arterioscler Thromb Vasc Biol 20:1724-1728, 2000
18. 2 receptor antagonist, S18886, prevents enhanced atherogenesis caused by diabetes mellitus. Circulation 112:3001-3008, 2005
19. Lassila M, Seah KK, Allen TJ, Thallas V, Thomas MC, Candido R, Burns WC, Forbes JM, Calkin AC, Cooper ME, Jandeleit-Dahm KA: Accelerated nephropathy in diabetic apolipoprotein e-knockout mouse: role of advanced glycation end products. J Am Soc Nephrol 15:2125-2138, 2004
20. Paigen B, Morrow A, Holmes PA, Mitchell D, Williams RA: Quantitative assessment of atherosclerotic lesions in mice. Atherosclerosis 68:231-240, 1987
21. Johns C, Gavras I, Handy DE, Salomao A, Gavras H: Models of experimental hypertension in mice. Hypertension 28:1064-1069, 1996
22. McCord JM, Fridovich I: Superoxide dismutase: an enzymic function for erythrocuprein (hemocuprein). J Biol Chem 244:6049-6055, 1969
23. Okado-Matsumoto A, Fridovich I: Assay of superoxide dismutase: cautions relevant to the use of cytochrome c, a sulfonated tetrazolium, and cyanide. Anal Biochem 298:337-342, 2001
24. Guo W, Adachi T, Matsui R, Xu S, Jiang B, Zou MH, Kirber M, Lieberthal W, Cohen RA: Quantitative assessment of tyrosine nitration of manganese superoxide dismutase in angiotensin II-infused rat kidney. Am J Physiol 285:H1396-H1403, 2003
25. Gu J, Wen Y, Mison A, Nadler JL: 12-lipoxygenase pathway increases aldosterone production, 3′,5′-cyclic adenosine monophosphate response element-binding protein phosphorylation, and p38 mitogen-activated protein kinase activation in H295R human adrenocortical cells. Endocrinology 144:534-543, 2003
26. 2+-ATPase function and lowers tyrosine nitration in hypercholesterolemia and improves nitric oxide-induced relaxation. Circ Res 90:1114-1121, 2002
27. Park L, Raman KG, Lee KJ, Lu Y, Ferran LJ Jr, Chow WS, Stern D, Schmidt AM: Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat Med 4:1025-1031, 1998
28. Spencer MW, Muhlfeld AS, Segerer S, Hudkins KL, Kirk E, LeBoeuf RC, Alpers CE: Hyperglycemia and hyperlipidemia act synergistically to induce renal disease in LDL receptor-deficient BALB mice. Am J Nephrol 24:20-31, 2004
29. Ziyadeh FN, Sharma K: Overview: combating diabetic nephropathy. J Am Soc Nephrol 14:1355-1357, 2003
30. Figarola JL, Scott S, Loera S, Tessler C, Chu P, Weiss L, Hardy J, Rahbar S: LR-90 a new advanced glycation endproduct inhibitor prevents progression of diabetic nephropathy in streptozotocin-diabetic rats. Diabetologia 46:1140-1152, 2003
31. 2 receptor-mediated apoptosis and adhesion molecule expression in cultured human aortic endothelial cells. Diabetes 51:198-203, 2002
32. Yamakura F, Taka H, Fujimura T, Murayama K: Inactivation of human manganese-superoxide dismutase by peroxynitrite is caused by exclusive nitration of tyrosine 34 to 3-nitrotyrosine. J Biol Chem 273:14085-14089, 1998
33. Kiyama S, Yoshioka T, Burr IM, Kon V, Fogo A, Ichikawa I: Strategic locus for the activation of the superoxide dismutase gene in the nephron. Kidney Int 47:536-546, 1995
34. Wang HD, Xu S, Johns DG, Du Y, Quinn MT, Cayatte AJ, Cohen RA: Role of NADPH oxidase in the vascular hypertrophic and oxidative stress response to angiotensin II in mice. Circ Res 88:947-953, 2001
35. Li JM, Shah AM: ROS generation by nonphagocytic NADPH oxidase: potential relevance in diabetic nephropathy. J Am Soc Nephrol 14:S221-S226, 2003
36. 2α, cytokines and endotoxin in the pig pulmonary artery. Br J Pharmacol 141:488-496, 2004
37. Kone BC: Nitric oxide in renal health and disease. Am J Kidney Dis 30:311-333, 1997
38. Raij L, Baylis C: Glomerular actions of nitric oxide. Kidney Int 48:20-32, 1995
39. Xia Y, Roman LJ, Masters BS, Zweier JL: Inducible nitric-oxide synthase generates superoxide from the reductase domain. J Biol Chem 273:22635-22639, 1998
40. Lee HY, Noh HJ, Gang JG, Xu ZG, Jeong HJ, Kang SW, Choi KH, Han DS: Inducible nitric oxide synthase (iNOS) expression is increased in lipopolysaccharide (LPS)-stimulated diabetic rat glomeruli: effect of ACE inhibitor and angiotensin II receptor blocker. Yonsei Med J 43:183-192, 2002
41. Komers R, Anderson S: Paradoxes of nitric oxide in the diabetic kidney. Am J Physiol 284:F1121-F1137, 2003
42. Hatley ME, Srinivasan S, Reilly KB, Bolick DT, Hedrick CC: Increased production of 12/15 lipoxygenase eicosanoids accelerates monocyte/endothelial interactions in diabetic db/db mice. J Biol Chem 278:25369-25375, 2003
43. George J, Afek A, Shaish A, Levkovitz H, Bloom N, Cyrus T, Zhao L, Funk CD, Sigal E, Harats D: 12/15-Lipoxygenase gene disruption attenuates atherogenesis in LDL receptor-deficient mice. Circulation 104:1646-1650, 2001
44. Roy P, Roy SK, Mitra A, Kulkarni AP: Superoxide generation by lipoxygenase in the presence of NADH and NADPH. Biochim Biophys Acta 1214:171-179, 1994
45. 2α by human monocytes: discriminate production by reactive oxygen species and prostaglandin endoperoxide synthase-2. J Biol Chem 271:8919-8924, 1996
46. 2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism. Proc Natl Acad Sci U S A 87:9383-9387, 1990